Acelyrin, Inc. has taken its time in coming to a sensible decision on izokibep. The company has terminated development of its IL-17A inhibitor izokibep in both hidradenitis suppurativa (HS) and psoriatic arthritis (PsA) after a Phase III trial in the former condition yielded positive but unremarkable data.
Acelyrin Belatedly Drops Izokibep In Its Lead Indications
The group has stopped further development of the IL-17A inhibitor in hidradenitis suppurativa and psoriatic arthritis, and intends to pivot to a thyroid eye disease therapy.
More from Strategy
More from Business
• By
Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.